Foundayo Dosing: Orforglipron Daily Oral Tablet Schedule (2026)
Eli Lilly's Foundayo (orforglipron) is an investigational daily oral GLP-1 tablet — here's the Phase 3 dosing protocol, expected FDA-approved schedule, and how oral daily compares to weekly injection.
Foundayo is Eli Lilly's brand name for orforglipron, an investigational small-molecule GLP-1 receptor agonist taken as a once-daily oral tablet. Unlike Rybelsus (oral semaglutide), Foundayo doesn't require fasting administration because orforglipron is a small molecule, not a peptide — it survives the GI tract on its own. As of May 2026, Foundayo is not yet FDA-approved; final dosing will be set by Eli Lilly's approved label.
Phase 3 Foundayo dosing protocol (ACHIEVE / ATTAIN)
| Step | Daily dose | Duration |
|---|---|---|
| Initiation | 3 mg | Weeks 1-4 |
| Step 1 | 6 mg | Weeks 5-8 |
| Step 2 | 12 mg | Weeks 9-12 |
| Step 3 | 24 mg | Weeks 13-16 |
| Target maintenance | 36 mg | Weeks 17+ |
Note: this is the Phase 3 protocol. Final FDA-approved dosing may differ (could include sub-max maintenance doses like 12, 24 mg as approved options similar to how Zepbound is approved at 5/7.5/10/12.5/15 mg).
Why oral daily vs weekly injection?
- No needles, no cold-chain. Oral tablets ship at room temperature; weekly injectable GLP-1 ships in temperature-controlled cold-chain packaging.
- Daily dose flexibility. Missed dose impact is smaller — miss one day vs miss one week.
- Adherence trade-off. Daily dosing has historically worse long-term adherence than weekly. Patients who prefer "set it and forget it" weekly schedules may stay better on injectables.
- Cost differential expected. Eli Lilly's pricing for Foundayo not yet announced. Existing Zepbound pricing ($1,069-$1,086/mo list) suggests Foundayo may price in a similar range, with potential for lower price given small-molecule manufacturing economics.
Currently available: weekly injection compounded GLP-1
Until Foundayo is FDA-approved and available, the highest-effectiveness GLP-1 weight-loss options are injectable: Wegovy / compounded semaglutide (14.9% mean weight loss STEP 1) and Zepbound / compounded tirzepatide (20.9% mean weight loss SURMOUNT-1). Trimi offers compounded semaglutide at $99/mo and tirzepatide at $125/mo annual plan via 503A pharmacy partners.
Currently available: weekly compounded GLP-1
$99/mo semaglutide or $125/mo tirzepatide via Trimi annual plan. Same active ingredients as Wegovy and Zepbound. Strong weight-loss outcomes available now, no wait for Foundayo approval.
Start your visitFAQs
What is Foundayo's dosing schedule?
Foundayo is Eli Lilly's brand name for orforglipron — an investigational oral once-daily GLP-1 receptor agonist tablet. Phase 3 ACHIEVE and ATTAIN trials used a dose-escalation schedule: weeks 1-4 at low dose (3 mg), then titration up to the target maintenance dose (typically 12-36 mg daily depending on tolerance and response). As of May 2026 Foundayo / orforglipron is NOT FDA-approved; final approved dosing will be set when Eli Lilly receives FDA approval.
How is orforglipron taken?
Once-daily oral tablet — no fasting requirement (unlike Rybelsus which requires empty-stomach administration). The published Phase 3 protocols dosed in the morning. Orforglipron is a small-molecule GLP-1 receptor agonist (not a peptide), so it survives the GI tract without specialized absorption enhancement.
When will Foundayo be available?
Eli Lilly indicated FDA approval submission in H1 2026 for type 2 diabetes (ACHIEVE) and chronic weight management (ATTAIN). Possible launch H2 2026 or early 2027. The Foundayo brand name is being prepared for the weight-management indication in some markets. Timeline subject to FDA review duration.
What weight loss does Foundayo / orforglipron produce?
ATTAIN-1 (chronic weight management): mean body weight reduction of ~14-15% at the highest investigational dose at 72 weeks — within striking distance of injectable semaglutide (14.9% STEP 1) and approaching injectable tirzepatide (20.9% SURMOUNT-1). Final approved label outcomes will be set when FDA reviews the data.
Is Foundayo available now through Trimi?
No. Trimi offers compounded semaglutide ($99/mo annual) and compounded tirzepatide ($125/mo annual) — both injection-only. Orforglipron / Foundayo is investigational and not yet FDA-approved; compounded oral GLP-1 alternatives exist but lack bioequivalence evidence vs injectable. When orforglipron is FDA-approved, Trimi will evaluate inclusion based on patient demand and regulatory status.
Foundayo vs Wegovy vs Zepbound dosing?
Foundayo (when approved): daily oral tablet, target dose 12-36 mg. Wegovy: weekly injection, target 2.4 mg. Zepbound: weekly injection, target 15 mg. Daily dosing has worse adherence over time than weekly injection for most patients, but Foundayo offers convenience (no needles, no cold-chain shipping).
Related reading
Disclaimer: Informational, not medical advice. Foundayo / orforglipron is investigational and not FDA-approved as of May 2026. Dosing references reflect Eli Lilly's published Phase 3 protocols (ACHIEVE-1, ATTAIN-1). Final approved dosing will be set by FDA-approved labeling. Compounded GLP-1 medications are not FDA-approved as finished drugs. **The FDA does not review or approve any compounded medications for safety or effectiveness.